{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:19:22Z","timestamp":1759033162872,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1124\/jpet.109.157388","type":"journal-article","created":{"date-parts":[[2009,10,15]],"date-time":"2009-10-15T02:24:32Z","timestamp":1255573472000},"page":"190-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist\/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity"],"prefix":"10.1016","volume":"332","author":[{"given":"Julie A.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radka","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Grauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel L.","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine M.","family":"Pulicicchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zo\u00eb A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Wantuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Rosenzweig-Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter","family":"Goutier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"van de Neut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rotella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf W.","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Broqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad E.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Pausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.157388_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0773.1982.tb01032.x","article-title":"Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade","volume":"51","author":"Arnt","year":"1982","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1124\/jpet.109.157388_bib2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/026988110201600403","article-title":"Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study","volume":"16","author":"Beyer","year":"2002","journal-title":"J Psychopharmacol"},{"issue":"427","key":"10.1124\/jpet.109.157388_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2005.00540.x","article-title":"The role of dopamine in reward and pleasure behavior-review of data from preclinical research","author":"Bressan","year":"2005","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1124\/jpet.109.157388_bib4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/336783a0","article-title":"Cloning and expression of a rat D2 dopamine receptor cDNA","volume":"336","author":"Bunzow","year":"1988","journal-title":"Nature"},{"key":"10.1124\/jpet.109.157388_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200727010-00001","article-title":"Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy","volume":"27","author":"Cassano","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1124\/jpet.109.157388_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.109.157388_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/sj.bjp.0703378","article-title":"Effects of chronic fluoxetine treatment in the presence and absence of (\u00b1)pindolol: a microdialysis study","volume":"130","author":"Dawson","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.109.157388_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.106.103382","article-title":"Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor","volume":"318","author":"Deecher","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.157388_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.104.075382","article-title":"WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity","volume":"313","author":"Dunlop","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.157388_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1056-8719(98)00035-5","article-title":"Characterization of 5-HT1A receptor functional coupling in cells expressing the human 5-HT1A receptor as assessed with the cytosensor microphysiometer","volume":"40","author":"Dunlop","year":"1998","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/jpet.109.157388_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.pnpbp.2007.03.005","article-title":"Bipolar disorder: how far are we from a rigorous definition and effective management?","volume":"31","author":"Emilien","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1124\/jpet.109.157388_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.107.133082","article-title":"Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)","volume":"325","author":"Hirst","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.157388_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine2B receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol Pharmacol"},{"year":"1996","series-title":"Guide for the Care and Use of Laboratory Animals","key":"10.1124\/jpet.109.157388_bib14"},{"key":"10.1124\/jpet.109.157388_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)00775-0","article-title":"Pharmacological characterisation of human 5-HT2 receptor subtypes","volume":"414","author":"Jerman","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.109.157388_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2003.10.025","article-title":"In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function","volume":"483","author":"Jordan","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.109.157388_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.109.157388_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.109.157388_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0163-7258(97)00004-1","article-title":"The olfactory bulbectomized rat as a model of depression: an update","volume":"74","author":"Kelly","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.109.157388_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.157388_bib21","first-page":"653","article-title":"Venlafaxine for the treatment of depressive episode during the course of schizophrenia","volume":"24","author":"Mazeh","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"2 Suppl","key":"10.1124\/jpet.109.157388_bib22","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.109.157388_bib23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/jpet.103.062463","article-title":"S32504, a novel naphthoxazine agonist at dopamine D3\/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole","volume":"309","author":"Millan","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.157388_bib24","first-page":"92","article-title":"Dopamine D(4) and D(2L) receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor","volume":"60","author":"Oak","year":"2001","journal-title":"Mol Pharmacol"},{"year":"1986","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1124\/jpet.109.157388_bib25"},{"key":"10.1124\/jpet.109.157388_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00023210-200822050-00002","article-title":"Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence","volume":"22","author":"Pae","year":"2008","journal-title":"CNS Drugs"},{"issue":"Suppl 4","key":"10.1124\/jpet.109.157388_bib27","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/S0924-977X(08)70332-8","article-title":"Effect of aripiprazole on behaviour and leukocyte phagocytosis in the olfactory bulbectomy model of depression in rats","volume":"18","author":"Pistovcakova","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.109.157388_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0024-3205(89)90461-X","article-title":"[3H]L-657,743 (MK-912): a new, high affinity, selective radioligand for brain alpha 2-adrenoceptors","volume":"44","author":"Pettibone","year":"1989","journal-title":"Life Sci"},{"key":"10.1124\/jpet.109.157388_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.brainres.2005.12.052","article-title":"Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503","volume":"1073","author":"Rosenzweig-Lipson","year":"2006","journal-title":"Brain Res"},{"key":"10.1124\/jpet.109.157388_bib30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/284472a0","article-title":"Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors","volume":"284","author":"Sanberg","year":"1980","journal-title":"Nature"},{"key":"10.1124\/jpet.109.157388_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1124\/jpet.109.157388_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.109.157388_bib33","first-page":"305","article-title":"Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia","volume":"18","author":"Silver","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1124\/jpet.109.157388_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0920-9964(00)00135-3","article-title":"Depression in schizophrenia: recognition and management in the USA","volume":"47","author":"Siris","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.109.157388_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4088\/JCP.v62n1201","article-title":"Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action","volume":"62","author":"Stahl","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.109.157388_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.109.157388_bib37","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston","year":"2004","journal-title":"Drugs"},{"key":"10.1124\/jpet.109.157388_bib38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.109.157388_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1568007024606195","article-title":"Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis","volume":"1","author":"Tamminga","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1124\/jpet.109.157388_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1471-4159.1980.tb06608.x","article-title":"Interactions of divalent cations and guanine nucleotides at alpha 2-noradrenergic receptor binding sites in bovine brain mechanisms","volume":"34","author":"U'Prichard","year":"1980","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.109.157388_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0920-9964(95)00013-C","article-title":"Cortical maldevelopment, antipsychotic drugs and schizophrenia: a search for common ground","volume":"16","author":"Weinberger","year":"1995","journal-title":"Schizophr Res"},{"key":"10.1124\/jpet.109.157388_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2005.06.035","article-title":"Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex","volume":"387","author":"Zocchi","year":"2005","journal-title":"Neurosci Lett"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524455900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524455900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.157388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:03:03Z","timestamp":1740016983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524455900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0022356524455900"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.157388","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist\/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.157388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}